%0 Journal Article
%A Perez de Isla, Leopoldo
%A Alonso, Rodrigo
%A Watts, Gerald F.
%A Mata, Nelva
%A Saltijeral Cerezo, Adriana
%A Muniz, Ovidio
%A Fuentes, Francisco
%A Luis Diaz-Diaz, Jose
%A de Andres, Raimundo
%A Zambon, Daniel
%A Rubio-Marin, Patricia
%A Barba-Romero, Miguel A.
%A Saenz, Pedro
%A Sanchez Munoz-Torrero, Juan F.
%A Martinez-Faedo, Ceferino
%A Miramontes-Gonzalez, Jose P.
%A Badimon, Lina
%A Mata, Pedro
%A SAFEHEART Investigators
%T Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia 5-Year SAFEHEART Registry Follow-Up
%D 2016
%@ 0735-1097
%U http://hdl.handle.net/10668/18806
%X BACKGROUND Familial hypercholesterolemia (FH) is the most common genetic disorder associated with premature atherosclerotic cardiovascular disease (ASCVD). There are sparse data on attainment of treatment targets; large registries that reflect real-life clinical practice can uniquely provide this information.OBJECTIVES We sought to evaluate the achievement of low-density lipoprotein cholesterol (LDL-C) treatment goals in FH patients enrolled in a large national registry.METHODS The SAFEHEART study (Spanish Familial Hypercholesterolemia Cohort Study) is a large, ongoing registry of molecularly defined patients with heterozygous FH treated in Spain. The attainment of guideline-recommended plasma LDL-C goals at entry and follow-up was investigated in relation to use of lipid-lowering therapy (LLT).RESULTS The study recruited 4,132 individuals (3,745 of whom were >= 18 years of age); 2,752 of those enrolled were molecularly diagnosed FH cases. Mean follow-up was 5.1 +/- 3.1 years; 71.8% of FH cases were on maximal LLT, and an LDL-C treatment target = 18 years of age); 2,752 of those enrolled were molecularly diagnosed FH cases. Mean follow-up was 5.1 +/- 3.1 years; 71.8% of FH cases were on maximal LLT, and an LDL-C treatment target
%K cardiovascular disease
%K LDL-receptor mutations
%K lipid-lowering therapy
%K low-density lipoprotein cholesterol
%K Guidance
%K Management
%K Ezetimibe
%K Mortality
%K Efficacy
%K Therapy
%K Disease
%K Cohort
%K Risk
%K Care
%~